An evaluation of nearly 19,000 patients with metastatic colorectal cancer supported clinical trial data that immunotherapy ...

Patients older than 65 years had similar clinical outcomes in response to immune checkpoint inhibitors as younger patients with cancer.

Patients who were positive for cytomegalovirus had more immune cells circulating in their blood before they started ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

This Research Topic is the second volume of the “Immune Responses Against Tumors - From the Bench to the Bedside” Community Series. Please see Volume I ...

Investigator studied current treatment patterns and attrition rates in metastatic clear cell renal cell carcinoma using a large, US nationwide cohort.

Approximately 90% of all kidney cancers involve renal cell carcinoma, against which researchers are racing to find more effective therapies. One of the major challenges in treating this and other ...

Considered to be one of the greatest revolutions in cancer treatment, immunotherapy enhances the immune system's ability to ...

A protein identified by researchers at UT Southwestern Medical Center may drive resistance to immune checkpoint inhibitors, a ...

Antigen-presenting cells (APCs), such as dendritic cells and macrophages, are essential for initiating and regulation of anti-tumor T cell responses.

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

Let us delve into some of the TLR agonists in the clinic and why the careful selection of these drugs is crucial.